Friday 6 November 2026 Export TAK’s income statement to Excel — free account

Takeda Pharmaceutical Co.

TAK Healthcare Drug Manufacturers Specialty & Generic

Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.

Revenue: +1.71%
EPS: −4.35%
Free cash flow: +54.9%
Total debt: −7.28%

Quarter to September 2026, against a year earlier

21.25 0.19 +0.90%

Follow TAK

Alert me

Market cap: $67.7B
P/E: 32.0×
Fwd P/E: —
Dividend yield: 1.45%
F-score: 4/9
Altman Z: 1.03
Beneish M: −2.65
Dividend safety: 25/100

Overview

Insider Decisions last twelve months

Sold, $m 15.22

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	17	2	—	2

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 67,700.00

Revenue ttm 29,991.30

Net income ttm 3,239.66

Free cash flow ttm 7,976.47

Net debt Q 25,963.87

Valuation

P/E 31.97

Forward P/E —

Price / sales 2.24

Forward P/S Powerpack

Price / FCF 8.42

Price / book 1.44

Financial health

Current ratio Q 1.15

Debt / equity Q 0.62

Interest coverage Q 3.15

Growth

Revenue growth Q +1.71%

Operating income growth Q +77.87%

EPS, this year +28.59%

EPS, next year A +31.96%

Revenue, next year A —

EPS, past 5 yrs —

EPS, next 5 yrs A +27.57%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 54.40%

10-year low 10-year high

P/S against its own 10 years 77.81%

10-year low 10-year high

P/B against its own 10 years 68.46%

10-year low 10-year high

EV/Sales against its own 10 years 79.94%

10-year low 10-year high

EV/FCF against its own 10 years 66.28%

10-year low 10-year high

Dividends

Yield: 1.45%
Annual rate: 0.31
Payout ratio: 46.5%
Growth, 2018–26: −17.2%/yr

1.40 ’18
1.25 ’19 −11
0.85 ’20 −32
0.80 ’21 −5
0.66 ’22 −18
0.63 ’23 −5
0.62 ’24 −2
0.66 ’25 +7
0.31 ’26 −53

paid change on the year, %

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	3,263	2,677	4,204	2,863
Receivables	4,814	4,787	5,784	5,735
Inventory	8,348	8,035	9,218	9,079
Other	1,230	1,142	1,192	1,206
	17,654	16,640	20,397	18,882

	2024	2025	2026	Q'26
Payables	3,778	3,139	3,243	3,063
ST’ Debt	2,534	3,623	3,380	2,526
Other	8,890	8,900	11,423	10,076
	15,960	16,543	18,692	16,402

Compound Annual Growth %

	10y	5y	3y
Sales	7.08%	(0.21%)	(0.07%)
Cash Flow	41.64%	(6.27%)	(1.68%)
Earnings	0.00%	0.00%	0.00%
Book Value	11.38%	0.15%	1.41%

Earnings Trends EPS, adjusted, against the consensus

Sep 2026 Estimate 0.31 Actual 0.51

0.16 0.27 0.38 0.49 0.60

Dec 2025 Miss −0.07

Mar 2026 Beat +0.07

Jun 2026 Beat +0.07

Sep 2026 Beat +0.20

Dec 2026 — Feb 4

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Dec 2025	0.55	0.48	Miss by 0.07
Mar 2026	0.21	0.28	Beat by 0.07
Jun 2026	0.41	0.48	Beat by 0.07
Sep 2026	0.31	0.51	Beat by 0.20
Dec 2026	0.45	—	Reports 4 February 2027

EPS $

	Jun	Sep	Dec	Mar	Year
’26	0.22	—	—	—	—
’26	0.27	—	—	—	(0.32)
’25	0.19	—	—	—	0.22
’24	0.21	(0.11)	0.23	(0.02)	0.30
’23	0.26	0.14	0.29	0.08	0.75
’22	0.58	0.13	0.17	(0.23)	0.65
’21	0.25	0.01	0.28	0.59	1.13

Fiscal quarters ending in the months shown.

Revenue $m

	Jun	Sep	Dec	Mar	Year
’26	7,685	—	—	—	—
’26	7,636	—	—	—	29,738
’25	7,731	—	—	—	30,238
’24	7,728	7,197	7,556	6,939	29,420
’23	7,488	7,217	7,786	7,313	29,803
’22	8,641	7,688	7,931	7,504	31,764
’21	7,457	7,416	8,033	7,153	30,059

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	804	1,917	—	—	—
’26	1,486	2,550	6,285	—	6,873
’25	1,090	1,934	5,511	—	6,977
’24	675	1,335	967	1,966	4,943
’23	649	1,549	2,655	2,378	7,231
’22	1,518	2,122	2,938	3,417	9,996
’21	1,357	2,328	2,171	3,647	9,503

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	161	1,568	—	—	—
’26	1,013	2,198	4,050	—	4,179
’25	208	1,486	3,618	—	4,472
’24	(1,291)	1,017	477	1,481	1,685
’23	(109)	1,306	2,309	(958)	2,549
’22	1,134	1,729	2,538	2,955	8,356
’21	980	2,306	1,785	2,645	7,717

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	TTM Sep ’26	Trend	10 yrs	2027e	2028e	2029e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	16,108	15,935	18,875	30,279	30,059	31,764	29,803	29,420	30,238	29,738	29,991		+7.0%	—	—	—	—
	Gross margin, %	67.74	71.99	68.54	66.89	131.09	68.99	69.11	66.54	65.51	65.12	65.85		(2.6) pt	Powerpack Takeda Pharmaceutical Co.’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	1,333	1,955	854	(559)	3,443	2,693	2,776	364	1,156	(940)	2,563		n/m
	EBT margin, %	8.28	12.27	4.52	(1.85)	11.45	8.48	9.31	1.24	3.82	(3.16)	8.55		(11.4) pt
	Net income	1,074	1,680	981	407	3,536	2,048	2,346	995	714	(1,004)	3,240		n/m
Per share, $
Per share, $	Revenue	10.31	10.20	9.82	9.72	9.62	10.16	9.60	9.40	9.58	9.44	9.49		(1.0%)
	Earnings	0.68	1.08	0.51	0.13	1.14	0.66	0.76	0.31	0.22	(0.32)	0.66		n/m
	Cash flow	1.56	2.18	1.54	1.98	3.04	3.20	2.33	1.58	2.21	2.18	0.00		+3.8%
	Capex	(0.65)	(0.72)	(0.39)	(0.61)	(0.57)	(0.52)	(1.51)	(1.04)	(0.79)	(0.86)	0.00		+3.1%
	Free cash flow	0.91	1.46	1.15	1.37	2.47	2.67	0.82	0.54	1.42	1.33	0.00		+4.3%
	Book value	11.60	11.63	24.17	13.97	15.58	16.18	15.15	16.04	14.50	15.57	0.00		+3.3%
	Shares, m	1,562	1,562	1,923	3,114	3,124	3,127	3,104	3,129	3,158	3,150	3,139		+8.1%
Valuation, ×
Valuation, ×	P/E	0.00	65.94	9.76	116.50	16.02	21.80	21.40	42.87	49.75	27.45	31.97		37.1
	P/S	2.38	2.40	1.92	1.56	1.90	1.41	1.72	1.45	1.59	1.94	2.24		1.8
	P/B	2.13	2.02	1.76	1.09	1.17	0.89	1.09	0.85	0.95	1.17	1.44		1.3
	EV/Sales	2.51	2.79	2.29	2.91	3.03	2.38	2.67	2.48	2.55	2.83	3.10		2.6
	EV/FCF	4.21	4.63	5.44	20.62	11.82	9.06	31.18	43.28	11.06	7.77	11.67		14.9
Cash, $m
Cash, $m	Operating cash flow	2,431	3,401	2,956	6,162	9,503	9,996	7,231	4,943	6,977	6,873	11,556		+12.2%
	Capex	(1,014)	(1,128)	(751)	(1,887)	(1,786)	(1,640)	(4,682)	(3,258)	(2,505)	(2,694)	(3,580)		+11.5%
	Free cash flow	1,417	2,273	2,206	4,275	7,717	8,356	2,549	1,685	4,472	4,179	7,976		+12.8%
Balance, $m
Balance, $m	Working capital	(980)	3,072	4,858	2,701	8,833	3,986	(621)	1,694	97	1,706	2,480		n/m
	Net debt	7,149	5,494	45,230	40,847	34,146	30,887	28,332	30,159	27,124	28,016	25,964		+16.4%
	Shareholders’ equity	18,125	18,157	46,472	43,493	48,665	50,583	47,025	50,191	45,777	49,042	46,728		+11.7%
Returns, %
Returns, %	ROA	2.96	4.34	1.21	0.34	2.95	1.72	2.13	0.96	0.72	(1.02)	0.00		(4.0) pt
	ROIC	3.58	5.75	1.26	0.68	17.72	3.15	3.01	1.15	1.94	0.03	0.00		(3.5) pt
	ROE	6.14	9.27	3.04	0.90	7.67	4.13	4.81	2.05	1.48	(2.12)	0.00		(8.3) pt
People
People	Employees	27,230	27,230	49,578	47,495	47,000	47,347	49,095	49,281	47,455	47,000	—		+6.3%
	Revenue/emp, $m	0.59	0.59	0.38	0.64	0.64	0.67	0.61	0.60	0.64	0.63	—		+0.8%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026 · fundamentals updated 2 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TAK Takeda Pharmaceutical Co.	$67.7B	32.0×	—	+1.71% (above 0%: growing)	−4.35% (below 0%: shrinking)	+54.88% (above 0%: growing)	66.66%	16.51%
TEVA Teva Pharmaceutical Industries Ltd.	$48.7B	92.6×	30.7×	−1.90% (below 0%: shrinking)	−47.18% (below 0%: shrinking)	−30.29% (below 0%: shrinking)	55.52%	16.25%	Compare
HLN Haleon PLC Sponsored ADR	$40.2B	20.5×	16.5×	−0.32% (below 0%: shrinking)	+40.00% (above 0%: growing)	−42.94% (below 0%: shrinking)	62.88%	25.36%	Compare
ZTS Zoetis Inc.	$33.9B	13.4×	14.2×	−0.24% (below 0%: shrinking)	+2.48% (above 0%: growing)	+17.43% (above 0%: growing)	72.73%	37.56%	Compare
UTHR United Therapeutics Corporation	$24.3B	19.7×	22.5×	+4.13% (above 0%: growing)	−21.65% (below 0%: shrinking)	−63.65% (below 0%: shrinking)	88.10%	36.97%	Compare
VTRS Viatris Inc.	$21.8B	— (loss-making)	82.6×	−0.28% (below 0%: shrinking)	n/m	+38.78% (above 0%: growing)	38.35%	6.97%	Compare
NBIX Neurocrine Biosciences, Inc.	$16.2B	23.0×	20.6×	+41.24% (above 0%: growing)	−3.67% (below 0%: shrinking)	+79.00% (above 0%: growing)	97.63%	29.51%	Compare
RDY Dr. Reddy's Laboratories Ltd	$12.1B	44.4×	30.7×	−10.09% (below 0%: shrinking)	−36.84% (below 0%: shrinking)	−70.49% (below 0%: shrinking)	52.13%	14.63%	Compare
ELAN Elanco Animal Health Incorporated	$11.8B	— (loss-making)	161×	+10.23% (above 0%: growing)	+450.00% (above 0%: growing)	+35.56% (above 0%: growing)	58.33%	7.97%	Compare
Median of peers	$23.0B	21.7×	26.6×	−0.26%	−3.67%	−6.43%	60.61%	20.81%

All 84 Drug Manufacturers Specialty & Generic stocks →

Takeda Pharmaceutical Co. (TAK) Latest News

30 Oct

Impact 3 · 7:14 AM · MarketBeat transcript

What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call

29 Oct

Impact 4 · 1:45 PM · The Motley Fool transcript

Takeda (TAK) Q2 2026 Earnings Call Transcript

Impact 4 · 3:43 AM · Investing.com

Takeda H1 profit rises on cost savings, currency gains; hikes FY outlook

Impact 4 · 2:36 AM · Business Wire

Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones

25 Oct

Impact 4 · 8:00 PM · PR Newswire

2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein

23 Oct

Impact 4 · 7:30 AM · Business Wire

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study

22 Oct

Impact 4 · 7:04 PM · MarketBeat

Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage

20 Oct

Impact 4 · 12:09 PM · Simply Wall St.

Disease Clearance Data Might Change The Case For Investing In Takeda (TSE:4502)

19 Oct

Impact 4 · 9:59 AM · biopharmadive.com

Merck KGaA bets on RNAi with $1.3B Silence buyout

Impact 4 · 5:30 AM · Business Wire

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

14 Oct

Impact 4 · 8:30 PM · Business Wire

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Impact 4 · 8:00 AM · Business Wire

Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026

1 Oct

Impact 4 · 11:08 AM

Will Zasocitinib’s Phase 3 Outperformance Reshape Takeda Pharmaceutical's (TSE:4502) Immunology-Driven Pipeline Narrative

Impact 3 · 3:08 PM · Simply Wall St.

Takeda (TSE:4502) Stock Looks Below Fair Value Even After A 120% Run

30 Sep

Impact 4 · 4:09 PM · Simply Wall St.

Takeda Pharmaceutical (TSE:4502) Could Be 13% Undervalued On Strong Phase 3 Psoriasis Data

Impact 4 · 4:12 AM · MT Newswires

Takeda Reports New Psoriasis Treatment Outperformed Competitor in Phase 3 Trial

Impact 4 · 1:00 AM · Business Wire

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

29 Sep

Impact 3 · 9:17 AM · Zacks

KROS Begins Dosing in Phase II Study With Rinvatercept in DMD

27 Sep

Impact 4 · 8:00 PM · PR Newswire

Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC

22 Sep

Impact 4 · 9:30 AM

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

17 Sep

Impact 4 · 1:08 PM

Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis?

14 Sep

Impact 4 · 3:00 AM

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations

10 Sep

Impact 3 · 7:24 AM · biopharmadive.com

Andy Plump, architect of Takeda’s R&D overhaul, to retire next year

9 Sep

Impact 4 · 8:24 AM

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life

2 Sep

Impact 3 · 5:50 AM · pharmaceutical-technology.com

Takeda and Weave Bio collaborate on AI-driven automation in drug development

1 Sep

Impact 3 · 9:00 AM

Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities

Impact 3 · 8:14 AM

The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones

31 Aug

Impact 4 · 12:38 PM

Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug

Impact 4 · 8:13 AM · biopharmadive.com

FDA OKs Takeda, Protagonist drug for rare blood cancer

28 Aug

Impact 4 · 6:40 PM

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

Takeda Pharmaceutical Co.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to March

Takeda Pharmaceutical Co. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Takeda Pharmaceutical Co. (TAK) Latest News

30 Oct

29 Oct

25 Oct

23 Oct

22 Oct

20 Oct

19 Oct

14 Oct

1 Oct

30 Sep

29 Sep

27 Sep

22 Sep

17 Sep

14 Sep

10 Sep

9 Sep

2 Sep

1 Sep

31 Aug

28 Aug

TAK metrics, ten years each

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to March

Takeda Pharmaceutical Co. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Takeda Pharmaceutical Co. (TAK) Latest News

30 Oct

29 Oct

25 Oct

23 Oct

22 Oct

20 Oct

19 Oct

14 Oct

1 Oct

30 Sep

29 Sep

27 Sep

22 Sep

17 Sep

14 Sep

10 Sep

9 Sep

2 Sep

1 Sep

31 Aug

28 Aug

TAK metrics, ten years each

Stockrow Weekly